Surveillance of Vaccine-Preventable Diseases Sample Clauses

Surveillance of Vaccine-Preventable Diseases. LPHA must conduct Surveillance within its Service Area in accordance with the Communicable Disease Administrative Rules, the Investigation Guidelines for Notifiable Diseases, the Public Health Laboratory User’s Manual, and the Model Standing Orders for Vaccine, available for review at: xxxx://xxxxxx.xxxxxx.xxxxxx.xxx/DiseasesConditions/CommunicableDisease xxxx://xxxxxx.xxxxxx.xxxxxx.xxx/LaboratoryServiceshttp://xxxxxx.xxxxxx.xxxxxx.xxx/PreventionW ellness/VaccinesImmunization/ImmunizationProviderResources/Pages/provresources.aspx
Sample 1Sample 2Sample 3See All (15)
AutoNDA by SimpleDocs
Surveillance of Vaccine-Preventable Diseases. LPHA must conduct disease surveillance within its Service Area in accordance with the Communicable Disease Administrative Rules, the Investigation Guidelines for Notifiable Diseases, the Public Health Laboratory Users Manual, and the Model Standing Orders for Vaccine, available for review at: • xxxx://xxx.xxxxxx.xxx/DHS/ph/acd/ • xxxx://xxx.xxxxxx.xxx/DHS/ph/phl/ • xxxx://xxx.xxxxxx.xxx/dhs/ph/imm/
Sample 1
Surveillance of Vaccine-Preventable Diseases. LPHA must conduct Surveillance within its Service Area in accordance with the Communicable Disease Administrative Rules, the Investigation Guidelines for Notifiable Diseases, the Public Health Laboratory User’s Manual, and the Model Standing Orders for Vaccine, available for review at: xxxx://xxxxxx.xxxxxx.xxxxxx.xxx/DiseasesConditions/CommunicableDisease xxxx://xxxxxx.xxxxxx.xxxxxx.xxx/LaboratoryServiceshttp://xxxxxx.xxxxxx.xxxxxx.xxx/PreventionWellness/VaccinesImmunization/ImmunizationProviderResources/Pages/provresources.aspx Adverse Events Following Immunizations. LPHA must complete and electronically file a VAERS form if: An adverse event following immunization administration occurs, as listed in "Reportable Events Following Immunization”, available for review at xxxx://xxxxx.xxx.xxx/professionals/index#Guidance1 An event occurs that the package insert lists as a contraindication to additional vaccine doses. OHA requests a 60-day and/or one year follow-up report to an earlier reported adverse event; or Any other event LPHA believes to be related directly or indirectly to the receipt of any vaccine administered by LPHA or others occurs within 30 days of vaccine administration, and results in either the death of the person or the need for the person to visit a licensed health care provider or hospital. Perinatal Hepatitis B Prevention, Screening and Documentation LPHA must provide Case Management services to all confirmed or suspect HBsAg-positive mother-infant pairs identified by LPHA or OHA in LPHA’s Service Area. Case Management will be performed in accordance with the Perinatal Hepatitis B Prevention Program Guidelines posted on the OHA website at xxxxx://xxxxxx.xxxxxx.xxxxxx.xxx/DiseasesConditions/CommunicableDisease/ReportingCommunicableDisease/ReportingGuidelines/Documents/hepbperi.pdf and must include, at a minimum: Screen for HBsAg status, or refer to a health care provider for screening of HBsAg status, all pregnant women receiving prenatal care from public prenatal programs. Work with birthing hospitals within LPHA’s Service Area when maternal screening and documentation of hepatitis B serostatus in the Electronic Birth Registration System drops below 95%. Work with birthing hospitals within LPHA’s Service Area when administration of the birth dose of hepatitis B vaccine drops below 80% as reported in the Electronic Birth Registration System. Ensure that laboratories and health care providers promptly report HBsAg-positive pregnant women to L...
Sample 1

Related to Surveillance of Vaccine-Preventable Diseases

  • Preventive Drugs When purchased at any pharmacy: Must be prescribed by a physician. See Prescription Drug section for details. $0 Not Covered

  • Infectious Diseases The Employer and the Union desire to arrest the spread of infectious diseases in the nursing home. To achieve this objective, the Joint Health and Safety Committee may review and offer input into infection control programs and protocols including surveillance, outbreak control, isolation, precautions, worker education and training, and personal protective equipment. The Employer will provide training and ongoing education in communicable disease recognition, use of personal protective equipment, decontamination of equipment, and disposal of hazardous waste.

  • Infection Control Consistent with the Centers for Disease Control and Prevention Guideline for Infection Control in Health Care Personnel, and University Policy 3364-109-EH-603, the parties agree that all bargaining unit employees who come in contact with patients in the hospital or ambulatory care clinics will need to be vaccinated against influenza when flu season begins each fall. The influenza vaccine will be offered to all health care workers, including pregnant women, before the influenza season, unless otherwise medically contraindicated or it compromises sincerely held religious beliefs.

  • Infectious Disease Where an employee produces documentary evidence that:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Vaccination and Inoculation (a) The Employer agrees to take all reasonable precautions, including in-service seminars, to limit the spread of infectious diseases among employees.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Treatment Program Testing The Employer may request or require an employee to undergo drug and alcohol testing if the employee has been referred by the employer for chemical dependency treatment or evaluation or is participating in a chemical dependency treatment program under an employee benefit plan, in which case the employee may be requested or required to undergo drug or alcohol testing without prior notice during the evaluation or treatment period and for a period of up to two years following completion of any prescribed chemical dependency treatment program.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

Time is Money Join Law Insider Premium to draft better contracts faster.